ARE YOU ON MOBILE? SEE THE AGENDA  HERE

 

Day 2- please make sure to arrive at the venue in advance to collect your badges, long queues will delay your attendance for the first session.

Day 2 Co-conferences April 11

Cancer & Immunotherapy
09:10

Using CAR T-cells to target hematologic malignancies and in solid tumors to demonstrate the possibility to design immunity at will for therapeutic application

  • Progress of chimeric antigen receptor (CAR) T-cells targeting CD19 on B-cells leukemias and lymphomas
  • Inducing durable complete responses in patients who are relapsed or refractory to all other available treatments 
  • Targeting new targets in hematologic malignancies and in solid tumors
Emerging Diseases
09:10

How new drivers of infectious diseases are changing the way we handle NTDs

  • Geographic significance: How NTDs are no longer limited to poverty driven areas only
  • Bringing together  the G20 countries to tackle this globally
Clinical Development April 11
09:10

Defining vaccine failure and addressing the many factors behind it

  • What do we mean by vaccine failure?
  • What are the factors that have to be in place before we conclude a vaccine “failed"
  • Looking at both immunogenicity and vaccine efficacy
Veterinary
09:10

Regulatory pathways to enable the licensing of veterinary vaccines

 
  • Addressing common regulatory pitfalls in the commercialization of new technologies and perspectives on the approaches to successful registration
  • Rapid licensing for emerging diseases
  • Perspectives on APHIS Memorandum 800.213 memo for licensing platforms
Bioprocessing & Manufacture
09:10

Designing and building the next generation of vaccine adjuvants

  • Key attributes necessary to generate well characterized adjuvant formulations
  • Vaccine/Adjuvant Delivery Issues & Systems
Cancer & Immunotherapy
09:40

Personalized cancer vaccines that target patients-specific mutations – a reality?

  • Neoantigen identification
  • Platforms amenable for neoantigen vaccination
  • Review of the recent clinical trial data  in the field of neoantigen vaccines
Influenza and Respiratory
09:40

An adenovirus vector based vaccine, expressing F antigen: Protecting young infants against RSV, by eliciting high titer, potent neutralising antibodies and T-cell immunity

  • Recombinant human adenoviral Ad26 and Ad35 vectors encoding the RSV F gene have the potential to provide broad and durable protection against RSV in human
  • Evaluating the safety, tolerability and immunogenicity
Emerging Diseases
09:40

How have we handled the Zika outbreak and what prevention measures have we taken as Zika continues to spread in the US?

  • How long until we are likely to be able to vaccinate vulnerable people that are most at risk?
  • Have we responded quickly enough?
  • What about the Zika virus we now understand and what prevention measure have been implemented to mitigate risks
Clinical Development April 11
09:40

Future of adjuvants – what is needed? Better strategy for a rational design

  • Improving the safety database and performance characteristics of QS-21, one of the leading adjuvant candidates
  • manufacturing sustainable source of synthetic QS-21 for vaccine development and trials
Veterinary
09:40

Examining legislation on veterinary vaccination and global practices for animal vaccination

 
  • Redefining the role of public sector and private sector veterinarians and technicians
  • Highlighting models of synergies between public and private sector veterinarians for animal vaccination
  • Epizootic diseases vaccination campaigns
  • Discussing mandates provided by the public sector to private veterinarians for vaccination campaigns
Bioprocessing & Manufacture
09:40

New compounds to improve the quality/stability of viral antigens in vaccine formulation

  • An innovative proprietary surfactant and detergent based approach consisting either on facilitating splitting of native viruses, fragmentation of bacteria, monitoring the solubilization and the stabilization of viral antigens without mutagenesis, truncation and fusion
  • Applying this to solubilize and stabilize functional tetramers of Matrix 2 ion channel from MDCK infected cells
  • Reporting a striking stabilization effect on native HIV envelop protein / spikes in favor of functional stem-exposed conformation as shown by neutralizing antibodies and GP41 interactions, mainly at the membrane proximal external region 
Emerging Diseases
10:10

Developing vaccines for emerging diseases: Addressing Zika, MERS and Ebola

  • Role of validated platforms in rapidly addressing emerging infectious diseases – safety and speed of development
  • Generating high level of immune responses in animal models and demonstrating challenge efficacy
  • Results from the first in human studies on safety and immunogenicity
Dr Scott M White, Vice President - Clinical Development, Inovio Pharmaceuticals
Clinical Development April 11
10:10

Encouraging results from clinical studies for a HIV vaccine

  • The need for better animal models to improve HIV vaccine development
  • The effects of changing a single amino acid in the envelope coat protein of naturally occurring HIV strains
  • Overview of clinical trials and vaccine platforms
10:40

Networking coffee break

Cancer & Immunotherapy
11:40

Use of biomarkers and immunotherapy in cancer and combinational studies

  • The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics
Dr Jianda Yuan, Director of Translational Immuno Oncology Research, Merck
Emerging Diseases
11:40

Addressing vaccine development against emerging mosquito-transmitted diseases

  • Building on key competencies from a successful bench to market development of a Japanese Encephalitis vaccine
  • Valneva’s vaccine candidates against Zika, Chikungunya and Yellow fever
Veterinary
11:40

Alleviating disparities between animal and human adjuvanted vaccines

 
  • One health perspective on how to exploit human and veterinary vaccines for therapeutic and preventative treatment across all species
  • Measuring efficacy, toxicity and correlates of protection
  • The future of adjuvants in preclinical and clinical development
Bioprocessing & Manufacture
11:40

Dry powder vaccine stabilization and delivery by spray drying

  • Methods and considerations for Spray dried macromolecules
  • Different Delivery Routes and their application to spray drying
  • Enteric Capsules for oral delivery and rapid pre-clinical development
  • Case Studies
Cancer & Immunotherapy
12:10

Using RNA based vaccines as delivery method to dendritic cells exploits antiviral defence for cancer immunotherapy

  • Overcoming the technical challenges that hinder delivery of vaccine antigens into dendritic cells (DCs)
  • How DCs can be targeted precisely and effectively in vivo using intravenously administration
Bioprocessing & Manufacture
12:10

Application of analytical and biophysical tools in development of oncolytic viruses

  • Development of an analytical virology platform to evaluate quality attributes and support process development for oncolytic viruses
  • Development and optimization of a robust set of bioanalytical and biophysical assays to characterize viral particles and their infective potency
  • Design and characterization of a recombinant Newcastle Disease Virus for oncolytic therapy and immune potentiation
Influenza and Respiratory
12:25

Mucosal Immune Responses in Clinical Studies with Oral Tablet Vaccines for the Prevention of Norovirus or Influenza

  • Preclinical studies have generated robust immune responses and provided complete protection against infection
  • Ph1 randomized, double-blind, placebo-controlled study to assess the safety and immunogenicity of the F-protein based RSV tablet vaccine
  • Applications of the oral platform to norovirus vaccine
Cancer & Immunotherapy
12:40

DNA vaccines as cancer therapeutics

  • Selection of Appropriate Vaccine Antigens for Prostate Cancer
  • Synergy of DNA Vaccines with Checkpoint Inhibitors
  • Three Ongoing Translational Trials of DNA Vaccines in Prostate Cancer
Influenza and Respiratory
12:40

New fragmentation and solubilization/ stabilization approaches: case study on the influenza

  • A new approach for solubilization/stabilization of membrane antigens as well as membrane fragmentation, suitable for novel efficient influenza vaccine development
  • Applications to other highly challenging vaccine candidates
Emerging Diseases
12:40

Design and implementation of clinical trials in an emerging epidemic: Flavivirus Case Study

  • Clinical development challenges associated with the design and conduct of emerging epidemic trials
  • Current status of Zika Vaccine candidates in Clinical Development
  • Geographical Considerations: Epidemiology v Trial Locations
  • Considerations for Zika Vaccine Clinical Development Strategy
Clinical Development April 11
12:40

Progress towards a CMV vaccine

  • Human CMV is implicated in a number of diverse diseases
  • Overview of recent vaccine developments and platforms
  • Preclinical progress towards a Pentamer based vaccine
Veterinary
12:40

Success story for alternative influenza platforms: Update on avian influenza vaccines

 
  • Developing poultry vaccines using insect cells
  • Baculovirus system in insect cells for avian influenza in poultry
  • Challenges faced and lessons learnt for future developments
Influenza and Respiratory
12:55

Results of a PhIa study of M2SR influenza vaccine in healthy adults

  • The promise of prevention: A novel universal vaccine virus based on deletion of a portion of the M2 gene
  • Protection from drifted or mismatched flu strains
  • Breadth of protection in multiple age groups
13:10

Networking Lunch & Poster Session

Cancer & Immunotherapy
14:40

Clinical and immunological predictors for lesion regression and viral clearance following HPV immunotherapy

  • Identification of immunological signatures that predict treatment outcomes with VGX-3100 therapy
  • Implications for cancer immunotherapy with tumor targeted antigens
  • Advancing combinatorial approaches with cancer vaccines that drive antigen specific CD8 T-cells
Influenza and Respiratory
14:40

The gold standard for human challenge studies in respiratory vaccines

  • The gold standard for human challenge studies in respiratory vaccines
  • Results of studies of antiviral or vaccine approaches in the human challenge model have been predictive of efficacy in the real world
  • What we’ve learnt: Sharing knowledge over 7 clinical studies involving more than 750+ volunteers for RSV
Emerging Diseases
14:40

The value of adjuvants and vaccines to be used to prevent disease and in post-exposure

  • Using host-directed therapeutics to prevent anti-microbial resistance
  • Mechanisms of the delivery in assisting the immune system to fight reoccurrence
  • Blurring the lines between the therapeutic and preventative nature of vaccines
  • Broadening the immune response using adjuvants for faster and longer-lasting effects
  • Rapid response techniques to contain outbreaks
Veterinary
14:40

Utilization of Next Generation Sequencing for selection of vaccine candidates for production animals

 
  • Analyzing full genomic sequences of bacteria isolates
  • Analyzing recombinant HVT vectors
  • Identification of subpopulations
]
Bioprocessing & Manufacture
14:40

Innovation and challenges for development and industrialization of vaccines: New technologies, process industrialization and analytics

  • Incorporating new technologies
  • Department covering New Biological Entities Process industrialization (Ph III and ownwards) Process and Analytics Life Cycle Management, Manufacturing Support
Cancer & Immunotherapy
15:10

Novel personalized immune therapies for solid tumors

  • Rationale for use of immunotherapy in glioblastoma
  • Mobilizing the immune system through patient specific biomarkers, obtained from their tumor
  • Providing a clinical update on the vaccine progress in patients
  • Strategy for design of a Ph III trial immunotherapy trial incorporating lessons learned during Ph II
  • Challenges with manufacturing personalized immunotherapy
Influenza and Respiratory
15:10

Fc-FcγR interactions of anti-influenza stalk mAbs: Mechanistic data to support universal flu vaccine development

  • Studying Fc receptor interactions: How are Abs working to give immunity?
  • Gaining optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies
  • Potential applications to other viruses  
Emerging Diseases
15:10

Development of a novel vaccine for protection against Lyme borreliosis: PhI trial of Valneva’s Lyme vaccine candidate VLA15

  • Supporting evidence from pre-clinical data of protection from Borrelia species pathogenic for humans
  • Product development and public health strategy
Bioprocessing & Manufacture
15:10

Process development for the production of vaccines and viral vectors in suspension culture of HEK293 cells

  • Suspension HEK293 cell line has been scaled up for GMP production of complex vaccines including virus like particles and vectors for high density production under serum-free condition
  • Currently used in clinical trials to develop vaccines
Bioprocessing & Manufacture
15:25

Semi-synthetic archaeal lipid adjuvants as platforms for induction of cell-mediated immunity to vaccines

  • A novel class of archaeal lipid adjuvants, currently developing a third generation of highly simplified, cost-effective semi-synthetic glycolipid adjuvants
Influenza and Respiratory
15:40

Developing new vaccine for H1N1 and H3N2 influenza A viruses

  • Advanced development of more effective universal influenza vaccines
  • Using Computationally Optimized Broadly Reactive Antigen (COBRA) - a major step in the right direction towards a universal vaccine
Emerging Diseases
15:40

Technologies to facilitate a rapid vaccine response to newly emerging pathogens

  • With the increasing number of emerging diseases, what technologies and platforms are available to help identify and prevent outbreaks?
  • New vaccines are all moving away from traditional vaccine approaches so how do we choose one platform over another?
  • Being prepared: Promising new platform technologies applicable for vaccine development against emerging pathogens
Clinical Development April 11
15:40

Correlates of protection induced by vaccines with emphasis on enteric vaccines

  • Why are correlates of protection important and how are they determined?
  • Lessons learnt from a collective of vaccine models and studies
  • The need to evaluate the consistency of vaccine production
Veterinary
15:40

Yeast-based vaccines: Merging high efficacy, easy antigen combination and advantageous cost of goods

 
  • A novel subunit marker vaccine technology based on milk-yeast
  • New validation data for the technology and vaccines targeting both capsid and enveloped viruses
  • Save >90 % of the manufacturing costs, due to cost effective fermentation, using a single production run for combi vaccines and lacking the need to purify antigens
16:10

Networking coffee break

Cancer & Immunotherapy
16:40

Oncolytic virus T-VEC shows therapeutic benefit against melanoma after randomized PhIII study

  • Designing a clinical trial for a new class of drugs – what to test and look for
  • Establishing the legitimacy of oncolytic viruses in cancer therapy, allowing more research in other types of viruses and in approaches where other viral vectors can be combined
  • Taking it outside of melanoma and theoretically to any cancer
Clinical Development April 11
16:40

Overcoming challenges in seasonal vaccine studies, including maternal immunization

  • Vaccine development against Clostridium difficile
  • How has the rise an AMR pushed the importance of these infections to immune compromised patients?
Veterinary
16:40

ELISpot and FluoroSpot in veterinary vaccine research

 
  • T-cell ELISpot assays and B-cell ELISpot assays in veterinary vaccine research
  • Novel potential of T and B-cell FluoroSpot assays in veterinary vaccine research
  • Why FluoroSpot and not intracellular cytokine staining and Flow cytometry?
Veterinary
16:55

Genetic cancer vaccines for pets: Cutting-edge technologies with high translational potential for humans

 
  • How relevant are preclinical models for developing Cancer Vaccines
  • How to combine new Cancer Vaccines with existing therapies
  • How to achieve local and systemic Cancer control
  • Moving towards innovative products: lessons learnt
Bioprocessing & Manufacture
16:55

A platform approach for viral vaccine manufacturing

  • Our platform approach for the manufacturing of viral vaccines
  • How technological developments help to set-up a robust and scalable process using single use technologies
Cancer & Immunotherapy
17:10

MVA, viral vector, past, present and future in immune-oncology

  • Combining our cancer vaccines with checkpoint inhibitors
  • Progress on the new PhII and PhIII trials results
Christopher Heery, Chief Medical Officer, Bavarian Nordic
Influenza and Respiratory
17:10

Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly

  • Phase 2 clinical results on QIV seasonal VLPs in healthy adults and elderly
  • Comparison of humoral and cell-mediated immune responses induced by VLPs
Emerging Diseases
17:10

An update on the safety, immunogenicity, and efficacy of the rVSVΔG-ZEBOV-GP Ebola Vaccine

  • Further results from three separate clinical trials to  distribute its vaccine by the end of 2017
  • Interim results demonstrated the vaccine’s ability to cut the risk of infection in people
  • Regulatory experience and lessons learned that could help with progressing the Zika outbreak
Clinical Development April 11
17:10

A cross-kingdom vaccine against fungal (Candida) & bacterial (Staph aureus) AMR pathogens

  • First efficacy established for an anti-fungal vaccine: Ph IIa results with NDV-3A
  • US Army collaboration using NDV-3A to prevent Staph aureus skin & soft tissue infections
  • NIH clinical study: Hyper-IgE Syndrome patients with recurrent Candida & Staph infections
Veterinary
17:10

Developing a novel vaccine for therapeutic treatment of cancer in companion animals

 
  • Clinical data demonstrating the progress in adaptive immunotherapy for cancer in companion animals
  • Harnessing the ability of the immune system to eradicate cancer and sharing mode of mechanism
  • Lessons learnt from developing an innovative and patented immunotherapy method to treat cancer in companion animals
Bioprocessing & Manufacture
17:10

IT innovations and their impact on vaccine bioprocessing and manufacturing development

  • Having the ability to interrogate manufacturing data
  • Bringing highly structured data and highly unstructured data together for analysis and aggregation
  • How to analyse production processes that are inherently variable
  • Lessons learned and progress made
Veterinary
17:25

Meeting the need for innovative antigen expression systems

 
  • Reengineering expression systems to for improved vaccine development
  • Discussing feasibility of scale-up expression
Cancer & Immunotherapy
17:40

Panel: For vaccines that are being paired with adjuvant or checkpoint blockade therapies, are we working with the right antigenic targets?

  • What technologies will enable a quick turnaround time for producing personalized vaccine formulations? What delivery systems are supported by the FDA?
  • How will combinational approaches reduce side effects and replace conventional treatments including chemotherapy?
  • Are we leveraging the power of biomarkers that pinpoint which patient subpopulations that would be the ideal candidates for a given immunotherapeutic regimen
  • Using patient’s genetic makeup to design and execute an optimal therapeutic strategy
  • Does the future involve companion diagnostics?
Emerging Diseases
17:40

Spike Trimers: A General Vaccine Solution for Beta-coronaviruses

  • Vaccine candidates in development: The current landscape
  • Targeting the MERS-CoV S protein
  • Immunogens based on full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice and non-human primates
Clinical Development April 11
17:40

Bioconjugate Shigella vaccine in clinical development

  • The development plan for a Shigella vaccine demonstrated in PhI and a PhIIB human challenge study
  • A regulatory tool for licensing
Veterinary
17:40

Vaccine research, trans-boundary diseases and the biodefence research programme

 
  • Control of highly specially-dangerous pathogens.
  • Developing vaccines engineered for the purpose of control and responding to disease outbreak
Bioprocessing & Manufacture
17:40

Continuous manufacturing: A reality only for bigger players?

  • Capital efficiency for continuous manufacturing techniques and facilities
  • Does the future include smaller players and CMOs?
  • Benefits to vaccine manufacturing and other biologics as we increasingly combine approaches
Influenza and Respiratory
18:10

Facilitated DMAb in vivo delivery for rapid protection from difficult immune targets

  • Major improvements in DNA vaccine technology over the past decade has reinvigorated this platform which has conceptual advantages over traditional vaccine platforms and for invivo antigen delivery
  • In humans prior generations of DNA vaccines were poorly immunogenic. Through multiple improvements including synthetic optimization, formulation technology and enhanced EP delivery this technology exhibits improved performance in vivo driving immune responses similar or superior to live viral vectors
  • We have refocused this approach for direct DNA (DMAb) delivery of Monoclonal antibodies targeting EID produced invivo and compare this approach to vaccination for rapid immune protection against important pathogens  
Emerging Diseases
18:10

Vaccine progression and developments against Malaria

  • The first malaria vaccine providing durable protection against infection with malaria parasites
  • PfSPZ vaccine has shown to provide protection against infection with malaria parasites for at least 14 months
  • Next steps to make the vaccine a reality to benefit the huge population still at risk
Clinical Development April 11
18:10

Development of Anthrax vaccine candidates

  • Development of single dose nasal spray anthrax vaccine
  • The potential threat to the national health security
  • Combating the health impacts of an anthrax attack
Veterinary
18:10

Can we eradicate FMD? An industry perspective

 
  • Global overview of FMD vaccine use
  • Different epidemiological situations, different needs
  • Trends and future evolutions in the FMD vaccine world
  • How vaccine manufacturers contribute to FMD control and eradication
Bioprocessing & Manufacture
18:10

Accelerating Vaccine Development & Biomanufacturing Using a Universal, Non-viral Delivery Platform for Engineering of Relevant Cell Types

  • Rapidly express mg to gram quantities of MAbs, recombinant proteins, viral vectors, and VLPs
  • Bench to bedside scalability in cells relevant to bioproduction (CHO, HEK, Vero, MDCK, BHK21, insect cells, etc.)
  • Synergize and streamline migration from transient expression to stable cell line generation
18:40

Chair’s closing remarks and close of congress day 2

18:45

Networking Drinks & Party

last published: 27/Mar/17 16:35 GMT